Literature DB >> 9890299

The effect of osteotomy on bowing and height in children with X-linked hypophosphatemia.

M T Rohmiller1, C Tylkowski, V M Kriss, R J Mier.   

Abstract

The clinical records of 40 patients with X-linked hypophosphatemia who were treated and followed for at least 36 months were examined retrospectively. The patients were divided into those treated with medication only (group A) and those treated with medication and surgery (group B). At follow-up, significant improvement in bowing angles was noted for group B patients compared with those treated medically. There was, however, no improvement in the height of children in group A, and there was a significant decrease in height among the children treated surgically (group B). Neither height nor bowing angles of femurs or tibias at presentation predicted the need for future osteotomies. However, children who eventually needed surgery were found to be obese at presentation significantly more frequently than children who did not require osteotomy.

Entities:  

Mesh:

Year:  1999        PMID: 9890299

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

Review 1.  [Hyperphosphatasia and hypophosphatasia in childhood].

Authors:  P Drees; D Schmidt; T Lewens; T Vetter; A Meurer
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

Review 2.  Hypophosphatemia and growth.

Authors:  Fernando Santos; Rocío Fuente; Natalia Mejia; Laura Mantecon; Helena Gil-Peña; Flor A Ordoñez
Journal:  Pediatr Nephrol       Date:  2012-11-22       Impact factor: 3.714

3.  Metabolic and orthopedic management of X-linked vitamin D-resistant hypophosphatemic rickets.

Authors:  Sandro F Fucentese; Thomas J Neuhaus; Leonhard E Ramseier; G Ulrich Exner
Journal:  J Child Orthop       Date:  2008-07-26       Impact factor: 1.548

4.  Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR).

Authors:  A Gizard; A Rothenbuhler; Z Pejin; G Finidori; C Glorion; B de Billy; A Linglart; P Wicart
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.